Immunogen (IMGN) Tops Q4 EPS by 4c, FY Revenue Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $12.27 million.
GUIDANCE:
Immunogen sees FY2019 revenue of $40-45 million, versus the consensus of $84.56 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OppFi Inc. (OPFI) Tops Q3 EPS by 2c ; Offers Guidance
- Materialise NV (MTLS) Reports In-Line Q3 EPS; reaffirms outlook
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
